NextGen Pulmocore 12 gene panel - PDL1 22C3
NextGen Pulmocore 12 gene panel - PDL1 22C3 ** Price
Brief Details
What Is a NextGen Pulmocore 12 Gene Panel - PDL1 22C3?
The NextGen Pulmocore 12 Gene Panel - PDL1 22C3 is a highly specialised diagnostic test used for patients diagnosed with lung cancer, particularly non-small cell lung cancer (NSCLC). It combines next-generation sequencing (NGS) technology with protein expression analysis to create a comprehensive molecular profile of your tumour.
This test helps detect specific genetic mutations and protein levels in lung cancer cells to guide personalised treatment decisions, moving beyond a one-size-fits-all approach to cancer care.
What Does the NextGen Pulmocore 12 Gene Panel - PDL1 22C3 Measure?
This combined test creates a detailed molecular profile of your lung tumour to identify the most effective treatments available:
- Genetic mutations: Checks for specific alterations in 12 genes known to drive cancer growth in lung cancer, including EGFR, ALK, ROS1, BRAF, MET, and KRAS
- Gene fusions: Detects when parts of different genes join together abnormally, which can drive cancer growth
- Copy number variations: Identifies when certain genes are duplicated or deleted in cancer cells
- Protein expression: Measures the amount of PD-L1 protein on cancer cell surfaces to predict response to immunotherapy.
NextGen Pulmocore 12 Gene Panel - PDL1 22C3: Who Needs It and Why It's Done
Who Should Get a NextGen Pulmocore 12 Gene Panel - PDL1 22C3?
The NextGen Pulmocore 12 Gene Panel - PDL1 22C3 is primarily recommended for specific patient groups:
- Patients diagnosed with non-small cell lung cancer (NSCLC)
- Patients with advanced or metastatic NSCLC (cancer that has spread)
- Patients being considered for targeted therapy or immunotherapy
- Patients whose doctors need to determine the best treatment approach
Why Is a NextGen Pulmocore 12 Gene Panel - PDL1 22C3 Done?
This test is done to personalise your cancer treatment by providing a "roadmap" of your tumour, helping your oncologist choose targeted therapies or immunotherapies that are more likely to be effective.
Importance of a NextGen Pulmocore 12 Gene Panel - PDL1 22C3
The clinical relevance of the NextGen Pulmocore 12 Gene Panel - PDL1 22C3 marks a significant shift towards precision medicine in cancer care. Instead of treating all lung cancers the same way, this test allows doctors to tailor treatment to the specific genetic makeup of your individual tumour.
By identifying key mutations, the test points directly to specific oral medications that can block cancer growth signals. The PD-L1 result helps determine if you're a good candidate for immunotherapy, which has dramatically improved survival rates for many patients with advanced lung cancer.
NextGen Pulmocore 12 Gene Panel - PDL1 22C3 Booking & Reports – Metropolis Healthcare India
How to Book a NextGen Pulmocore 12 Gene Panel - PDL1 22C3?
- Simple Online Booking
Booking can be done through the Metropolis Healthcare App or website. Select the 'NextGen Pulmocore 12 gene panel - PDL1 22C3', choose a convenient time slot, and visit the nearest Metropolis Lab.
- Sample Tracking Updates
Stay informed at every step. From collection to testing, you can track your sample directly through the Metropolis Healthcare website.
- Accurate Laboratory Testing
Your sample is processed at our NABL & CAP accredited laboratories, where expert technicians ensure accurate results.
- Quick & Easy Reports
Receive your test reports promptly via email, WhatsApp, or by downloading them directly from the Metropolis Healthcare website or app.
Is Home Sample Collection for the NextGen Pulmocore 12 Gene Panel - PDL1 22C3 Available Near You?
Home sample collection isn't applicable for the NextGen Pulmocore 12 Gene Panel - PDL1 22C3, as it requires a tissue sample from your tumour, which must be collected through a biopsy procedure at a medical facility. However, Metropolis Healthcare offers convenient access to this specialised test through our network of NABL & CAP accredited laboratories. Our expert pathologists and advanced technology ensure accurate results that help guide your treatment decisions with confidence.
How Long Does It Take to Get a NextGen Pulmocore 12 Gene Panel - PDL1 22C3 Report?
Reports are usually available within 15 days once the sample reaches the pathology lab.
Note: Reporting time may vary depending on your location.
Where Can I See or Get NextGen Pulmocore 12 Gene Panel - PDL1 22C3 Results?
Test results from Metropolis Healthcare can be accessed through multiple convenient channels. You can log in to the Metropolis website using your credentials or use the Metropolis Healthcare App to view and download your reports. Additionally, test reports are sent via email or WhatsApp, and you also have the option to collect a physical copy directly from the lab.
Interpreting NextGen Pulmocore 12 Gene Panel - PDL1 22C3 Results
What Your NextGen Pulmocore 12 Gene Panel - PDL1 22C3 Results May Indicate
Your test results provide crucial information about your tumour's genetic makeup and protein expression. Here's what the results typically show:
|
Parameter |
Result Type |
Mutation Detected |
No Mutation Detected |
|
Hotspot Genes (SNVs/Indels) |
Mutation status |
Indicates potential eligibility for targeted therapies specific to detected gene alterations |
Standard treatment options may be considered. |
|
Gene Fusions |
Fusion detection |
Identifies actionable gene fusions that may respond to fusion-targeted therapies |
No fusion-driven targets identified |
|
MET Exon 14 Skipping Mutation |
Splice variant detection |
Suggests sensitivity to MET inhibitors |
No MET exon 14 skipping variant detected |
|
Copy Number Variations (CNVs) |
Gene amplification status |
May indicate potential benefit from targeted therapy, depending on amplification level |
No clinically significant amplification detected |
Conditions that May Affect NextGen Pulmocore 12 Gene Panel - PDL1 22C3 Accuracy
Several factors can influence the accuracy of your test results:
- Insufficient tissue sample quality or quantity may affect testing.
- Previous treatment with chemotherapy or radiation may alter genetic markers.
- Tissue fixation methods and storage conditions can impact DNA quality.
- Tumour heterogeneity (different genetic patterns within the same tumour) may affect results.
- Sample contamination with normal tissue cells may dilute cancer cell signals.
How Is a NextGen Pulmocore 12 Gene Panel - PDL1 22C3 Done?
The NextGen Pulmocore 12 Gene Panel - PDL1 22C3 process involves several carefully coordinated steps:
- Your doctor will arrange for a tissue biopsy to obtain a sample from your tumour.
- The tissue sample is processed and embedded in paraffin blocks (FFPE blocks).
- DNA is extracted from the cancer cells within the tissue sample.
- Next-generation sequencing technology analyses multiple genes simultaneously.
- PD-L1 protein expression is measured using specialised antibody staining.
- Expert pathologists interpret the complex genetic and protein data.
- A comprehensive report is generated detailing all findings.
How Should You Prepare for a NextGen Pulmocore 12 Gene Panel - PDL1 22C3?
Preparing for the NextGen Pulmocore 12 Gene Panel - PDL1 22C3 involves coordinating with your healthcare team:
- No fasting required: You can eat and drink normally before the tissue collection.
- Bring complete medical history: Include all previous cancer treatments and medications.
- Provide histopathology reports: Your doctor will need previous biopsy results.
- Discuss current medications: Inform your doctor about all medicines and supplements you take.
- Follow biopsy preparation instructions: Your doctor will provide specific guidance for the tissue collection procedure.
Diseases that a NextGen Pulmocore 12 Gene Panel - PDL1 22C3 Can Help Detect
This specialised test helps identify specific characteristics of lung cancer that guide treatment decisions:
- Non-small cell lung cancer (NSCLC) with actionable mutations
- Lung adenocarcinoma with EGFR mutations
- ALK-positive lung cancers
- ROS1-positive lung cancers
- Lung cancers are suitable for immunotherapy based on PD-L1 expression.
- Tumours with MET amplification or exon 14 skipping mutations
NextGen Pulmocore 12 Gene Panel - PDL1 22C3/Packages that You Can Book With Metropolis Healthcare
Metropolis Healthcare offers comprehensive cancer screening and diagnostic packages that complement this specialised test:
|
Test/Package Name |
Purpose/Highlights |
|
Comprehensive lung cancer screening and diagnosis |
|
|
Alternative PD-L1 testing method for immunotherapy guidance |
|
|
Rapid tuberculosis detection for differential diagnosis |
|
|
Basic blood analysis to monitor overall health |
|
|
Heart function assessment before cancer treatment |
Frequently asked questions
Find quick answers to the most common questions about health tests, bookings, and reports.
Regular exercise, a balanced diet, avoiding smoking, maintaining a healthy weight, and managing stress all help reduce heart disease risk.
Common signs include irritability, trouble sleeping, headaches, difficulty concentrating, and muscle tension.
Ratings & Reviews
We're satisfying our customers every day since 1980.
Choose precision On time, every time!
- 98% on time collections with a 60 minutes promise
- Real-time tracking of phlebotomist arrival and report generation
- Fully digital report delivery—view from mobile or desktop instantly
- Continuous monitoring of turnaround times to ensure accuracy and speed
- Dedicated support team to resolve any delays or queries quickly
Why Metropolis Healthcare?
Metropolis has been present for over 40 years in the market.
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
0
Years of experience
170+
Advanced Labs
Trusted by
Leading Doctors & Hospitals
2,000+
Scientific Officers
Proficiency Testing
for Accurate Reports
Latest Blogs & News
Stay informed with our expert insights and updates.
About Us
Metropolis Healthcare is a leading diagnostic service provider in India. We are a team of dedicated professionals committed to ensuring you and your family receive the most accurate and timely healthcare solutions. We believe in making health care accessible, affordable and evidence-based. Our expert panel are equipped with the latest technology and manned by a certified team of over 4000+ technicians.
In diagnostic services, we have more than three decades of experience servicing diverse stakeholders health advantage packages for men, women and seniors, genetic fitness & corporation in over 650+ tests like Oncology, Neurology, Gynaecology, Haematology, and many more. Our diagnostic services are located in leading doctors and clinics and serve over 15+ cities in India.